Search Results - "Kappos, L"

Neurofilaments as biomarkers in neurological disorders by Khalil, Michael, Teunissen, Charlotte E., Otto, Markus, Piehl, Fredrik, Sormani, Maria Pia, Gattringer, Thomas, Barro, Christian, Kappos, Ludwig, Comabella, Manuel, Fazekas, Franz, Petzold, Axel, Blennow, Kaj, Zetterberg, Henrik, Kuhle, Jens

“…Neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders. Reliable quantification and longitudinal follow-up…”
Get full text

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis by Hauser, Stephen L, Bar-Or, Amit, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Montalban, Xavier, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Wolinsky, Jerry S, Arnold, Douglas L, Klingelschmitt, Gaelle, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Chin, Peter, Mairon, Nicole, Garren, Hideki, Kappos, Ludwig

“…In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse…”
Get full text

The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue by Penner, IK, Raselli, C., Stöcklin, M., Opwis, K., Kappos, L., Calabrese, P.

“…Fatigue symptoms are reported by a majority of patients with multiple sclerosis (MS). Reliable assessment, however, is a demanding issue as the symptoms are…”
Get full text

Clinical outcomes of natalizumab- associated progressive multifocal leukoencephalopathy by VERMERSCH, P, KAPPOS, L, GOLD, R, FOLEY, J. F, OLSSON, T, CADAVID, D, BOZIC, C, RICHMAN, S

“…Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection…”
Get full text

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis by Mehling, M, Johnson, T A, Antel, J, Kappos, L, Bar-Or, A

“…The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple…”
Get full text

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis by Manouchehrinia, Ali, Stridh, Pernilla, Khademi, Mohsen, Leppert, David, Barro, Christian, Michalak, Zuzanna, Benkert, Pascal, Lycke, Jan, Alfredsson, Lars, Kappos, Ludwig, Piehl, Fredrik, Olsson, Tomas, Kuhle, Jens, Kockum, Ingrid

“…OBJECTIVETo investigate the association between plasma neurofilament light chain (pNfL) levels and the risk of developing sustained disability worsening…”
Get full text

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis by Mehling, M, Lindberg, R, Raulf, F, Kuhle, J, Hess, C, Kappos, L, Brinkmann, V

“…FTY720 is a sphingosine 1-phosphate (S1P) receptor modulator that showed efficacy in phase II and III clinical trials in patients with multiple sclerosis (MS)…”
Get full text

Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis by Granziera, Cristina, Wuerfel, Jens, Barkhof, Frederik, Calabrese, Massimiliano, De Stefano, Nicola, Enzinger, Christian, Evangelou, Nikos, Filippi, Massimo, Geurts, Jeroen J G, Reich, Daniel S, Rocca, Maria A, Ropele, Stefan, Rovira, Àlex, Sati, Pascal, Toosy, Ahmed T, Vrenken, Hugo, Gandini Wheeler-Kingshott, Claudia A M, Kappos, Ludwig

“…Quantitative MRI provides biophysical measures of the microstructural integrity of the CNS, which can be compared across CNS regions, patients, and centres. In…”
Get full text

MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial by GROSSMAN, P, KAPPOS, L, GENSICKE, H, D'SOUZA, M, MOHR, D. C, PENNER, I. K, STEINER, C

“…Health-related quality of life (HRQOL) is often much reduced among individuals with multiple sclerosis (MS), and incidences of depression, fatigue, and anxiety…”
Get full text

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy by Francis, G, Kappos, L, O’Connor, P, Collins, W, Tang, D, Mercier, F, Cohen, JA

“…Background: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. Objective: The objective of this article is…”
Get full text

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis by O'CONNOR, P. W, GOODMAN, A, KAPPOS, L, LUBLIN, F. D, MILLER, D. H, POLMAN, C, RUDICK, R. A, ASCHENBACH, W, LUCAS, N

“…Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of…”
Get full text

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies by Havrdova, E., Giovannoni, G., Gold, R., Fox, R. J., Kappos, L., Phillips, J. Theodore, Okwuokenye, M., Marantz, J. L.

“…Background and purpose Significant effects on clinical/neuroradiological disease activity have been reported in patients with relapsing–remitting multiple…”
Get full text

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome by Kuhle, Jens, Gaiottino, Johanna, Leppert, David, Petzold, Axel, Bestwick, Jonathan P, Malaspina, Andrea, Lu, Ching-Hua, Dobson, Ruth, Disanto, Giulio, Norgren, Niklas, Nissim, Ahuva, Kappos, Ludwig, Hurlbert, John, Yong, V Wee, Giovannoni, Gavin, Casha, Steven

“…Background Neurofilaments (Nf) are major structural proteins that occur exclusively in neurons. In spinal cord injury (SCI), the severity of disease is…”
Get full text

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis by Kuhle, J., Lindberg, R. L. P., Regeniter, A., Mehling, M., Steck, A. J., Kappos, L., Czaplinski, A.

“…Background and purpose:  Amyotrophic lateral sclerosis (ALS) is classically assumed to be a neurodegenerative disorder. Inflammation has been observed in CNS…”
Get full text

Mind the gap: from neurons to networks to outcomes in multiple sclerosis by Chard, Declan T., Alahmadi, Adnan A. S., Audoin, Bertrand, Charalambous, Thalis, Enzinger, Christian, Hulst, Hanneke E., Rocca, Maria A., Rovira, Àlex, Sastre-Garriga, Jaume, Schoonheim, Menno M., Tijms, Betty, Tur, Carmen, Gandini Wheeler-Kingshott, Claudia A. M., Wink, Alle Meije, Ciccarelli, Olga, Barkhof, Frederik

“…MRI studies have provided valuable insights into the structure and function of neural networks, particularly in health and in classical neurodegenerative…”
Get full text

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis by MEHLING, M, BRINKMANN, V, ANTEL, J, BAR-OR, A, GOEBELS, N, VEDRINE, C, KRISTOFIC, C, KUHLE, J, LINDBERG, R. L. P, KAPPOS, L

“…The oral immunomodulator FTY720 has shown efficacy in patients with relapsing multiple sclerosis (MS). FTY720 functionally antagonizes sphingosine 1-phosphate…”
Get full text

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes by KAPPOS, L, POLMAN, C. H, POHL, C, SANDBRINK, R, FREEDMAN, M. S, EDAN, G, HARTUNG, H. P, MILLER, D. H, MONTALBAN, X, BARKHOF, F, BAUER, L, JAKOBS, P

“…To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple…”
Get full text

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults by Cortese, Rosa, Battaglini, Marco, Prados, Ferran, Bianchi, Alessia, Haider, Lukas, Jacob, Anu, Palace, Jacqueline, Messina, Silvia, Paul, Friedemann, Wuerfel, Jens, Marignier, Romain, Durand-Dubief, Françoise, de Medeiros Rimkus, Carolina, Callegaro, Dagoberto, Sato, Douglas Kazutoshi, Filippi, Massimo, Rocca, Maria Assunta, Cacciaguerra, Laura, Rovira, Alex, Sastre-Garriga, Jaume, Arrambide, Georgina, Liu, Yaou, Duan, Yunyun, Gasperini, Claudio, Tortorella, Carla, Ruggieri, Serena, Amato, Maria Pia, Ulivelli, Monica, Groppa, Sergiu, Grothe, Matthias, Llufriu, Sara, Sepulveda, Maria, Lukas, Carsten, Bellenberg, Barbara, Schneider, Ruth, Sowa, Piotr, Celius, Elisabeth G, Proebstel, Anne-Katrin, Yaldizli, Özgür, Müller, Jannis, Stankoff, Bruno, Bodini, Benedetta, Carmisciano, Luca, Sormani, Maria Pia, Barkhof, Frederik, De Stefano, Nicola, Ciccarelli, Olga

“…Abstract MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating…”
Get full text